Afatinib, alectinib, amivantamab, gefitinib, necitumumab, osimertinib and pemetrexed are now listed in the interaction checker as cancer drugs and interactions can be found with all comedications.
- Afatinib (Giotrif®, Gilotrif®) is an EGFR tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
- Alectinib (Alecensa®) is an ALK tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
- Amivantamab (Rybrevant®) is a monoclonal antibody and is indicated for the treatment of non-small cell lung cancer.
- Gefitinib (Iressa®) is an EGFR tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
- Necitumumab (Portazza®) is a monclonal antibody and is indicated for the treatment of non-small cell lung cancer.
- Osimertinib (Tagrisso®) is an EGFR tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
- Pemetrexed (Alimta®, Pemfexy®, Ciambra®) is an antimetabolite and is indicated for the treatment of non-small cell lung cancer and mesothelioma.
